Chugai’s Reduced Tamiflu Sales, Fallout From Sanofi-Aventis Deal Attribute To 35% Earnings Drop
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai attributed the 35 percent revenue decrease since January to reduced sales of influenza drug Tamiflu and the dissolving of its marketing arrangement with Sanofi-Aventis. Other negative factors affecting sales were the lowering of the price for recombinant human erythropoietin, Epogin, and reduced royalty and milestone income